Literature DB >> 11162920

Patients with Alzheimer's disease display a pro-inflammatory phenotype.

E J Remarque1, E L Bollen, A W Weverling-Rijnsburger, J C Laterveer, G J Blauw, R G Westendorp.   

Abstract

BACKGROUND: Inflammation plays a pivotal role in amyloid plaque progression thereby contributing to Alzheimer's disease-related neurodegeneration. We hypothesized that patients with Alzheimer's disease have an innate pro-inflammatory phenotype, as compared to control subjects without dementia.
METHODS: Patients with a diagnosis of probable Alzheimer's disease (n=12) and control subjects without signs of dementia (n=18) were enrolled. Whole blood samples were stimulated ex vivo with endotoxin under standard conditions. Cytokine levels were assessed by ELISA and compared by Mann-Whitneyll-test after log transformation.
RESULTS: Patients with Alzheimer's disease had seven- to ten-fold higher IL-1beta production relative to the amount of IL-10 both at the low (p=0.006) and high concentration of endotoxin (p=0.007). Subjects who display a pro-inflammatory phenotype as defined by a high IL-1beta/IL-10 ratio had 13.0-fold higher odds (95% CI: 2.1-82) to have dementia.
CONCLUSION: The data support the hypothesis that a pro-inflammatory phenotype contributes to the development of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162920     DOI: 10.1016/s0531-5565(00)00176-5

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  26 in total

Review 1.  Aging-related changes in neuroimmune-endocrine function: implications for hippocampal-dependent cognition.

Authors:  Ruth M Barrientos; Matthew G Frank; Linda R Watkins; Steven F Maier
Journal:  Horm Behav       Date:  2012-02-18       Impact factor: 3.587

Review 2.  The role of inflammatory processes in Alzheimer's disease.

Authors:  G Joseph Broussard; Jennifer Mytar; Rung-chi Li; Gloria J Klapstein
Journal:  Inflammopharmacology       Date:  2012-04-26       Impact factor: 4.473

Review 3.  Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects.

Authors:  Agnes L F Chan; Yie W Chien; Shun Jin Lin
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

4.  An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines.

Authors:  I Dafnis; A K Tzinia; E C Tsilibary; V I Zannis; A Chroni
Journal:  Neuroscience       Date:  2012-03-14       Impact factor: 3.590

5.  Intranasal Insulin Administration Ameliorates Streptozotocin (ICV)-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Memory Impairment in Rats.

Authors:  N Rajasekar; Chandishwar Nath; Kashif Hanif; Rakesh Shukla
Journal:  Mol Neurobiol       Date:  2016-10-11       Impact factor: 5.590

6.  Memory impairments in healthy aging: Role of aging-induced microglial sensitization.

Authors:  Ruth M Barrientos; Matthew G Frank; Linda R Watkins; Steven F Maier
Journal:  Aging Dis       Date:  2010-01-01       Impact factor: 6.745

7.  Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease.

Authors:  Daniela L Krause; Norbert Müller
Journal:  Int J Alzheimers Dis       Date:  2010-06-14

Review 8.  Sex and gender in psychoneuroimmunology research: past, present and future.

Authors:  Beth D Darnall; Edward C Suarez
Journal:  Brain Behav Immun       Date:  2009-03-09       Impact factor: 7.217

9.  Resolution of inflammation is altered in Alzheimer's disease.

Authors:  Xiuzhe Wang; Mingqin Zhu; Erik Hjorth; Veronica Cortés-Toro; Helga Eyjolfsdottir; Caroline Graff; Inger Nennesmo; Jan Palmblad; Maria Eriksdotter; Kumar Sambamurti; Jonathan M Fitzgerald; Charles N Serhan; Ann-Charlotte Granholm; Marianne Schultzberg
Journal:  Alzheimers Dement       Date:  2014-02-12       Impact factor: 21.566

10.  Does neuroinflammation fan the flame in neurodegenerative diseases?

Authors:  Tamy C Frank-Cannon; Laura T Alto; Fiona E McAlpine; Malú G Tansey
Journal:  Mol Neurodegener       Date:  2009-11-16       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.